Shares of Sun Pharmaceutical Industries climbed sharply after the company posted a strong earnings performance, signaling improving fundamentals and renewed investor confidence. The results reflected healthy revenue growth, firmer margins, and effective cost control, even as the global pharmaceutical industry grapples with pricing pressure and regulatory oversight. Investors responded positively to signs of operational stability and a favorable product mix, viewing the earnings as confirmation of the company’s strategic direction.